InVision Medical Technology
FDA-cleared AI for echocardiography: LVEF, amyloid detection, and beyond.
InVision sets the evidence bar for AI in echo: two FDA clearances, a published RCT, and a live CPT code. Enterprise-only and contact-priced, it's purpose-built for large health systems—not independent clinics. If your organization prioritizes peer-reviewed validation and regulatory rigor over speed-to-market, InVision is the safest bet.
Verified 6d ago · liveness 49/100 · cite: rightaichoice.com/tools/invision-medical-technology
- Health system leaders seeking enterprise-grade AI with proven ROI and CPT reimbursement
- Cardiology service line directors standardizing echo interpretation across multiple sites
- Echo lab directors and sonographers aiming to reduce measurement variability and turnaround time
- Core labs and clinical research organizations needing regulatory-grade quantification
- Hospitals without existing DICOM echo infrastructure or PACS/EHR integration
- Clinics needing real-time, scanner-integrated AI (post-processing only)
- Organizations seeking a free or low-cost AI solution with self-service signup
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip InVision if you're a small clinic or independent practice without enterprise PACS/EHR infrastructure, need real-time scanner-integrated AI, or require self-service, transparent pricing and quick onboarding.
No public pricing; you need to request a demo or contact sales, which may involve a lengthy procurement process.
InVision is contact-priced, fitting large health systems with dedicated IT and budget for enterprise AI. Compared to cheaper, self-service AI tools (e.g., Us2.ai) that offer per-study pricing, InVision's value is in its regulatory grade, peer-reviewed evidence, and reimbursement codes, justifying a higher price for organizations that prioritize evidence and ROI.
In short
InVision Medical Technology — FDA-cleared AI for echocardiography: LVEF, amyloid detection, and beyond. Best for Health system leaders seeking enterprise-grade AI with proven ROI and CPT reimbursement, Cardiology service line directors standardizing echo interpretation across multiple sites, Echo lab directors and sonographers aiming to reduce measurement variability and turnaround time. Contact Sales pricing.
What people actually say about InVision Medical Technology — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
- +FDA-cleared for LVEF and cardiac amyloid detection
- +Clinically validated in Nature, Nature Medicine, JAMA
- +Integrates with PACS, Epic EHR, DICOM workflows
- +No new hardware required – works with existing scanners
- +CPT Category III code enables reimbursement for AI use
- −No real-world user testimonials or community reviews
- −High enterprise cost with no public pricing information
- −Narrow focus on echocardiography limits applicability
- −Unproven in varied clinical settings outside research
- −Future products may face delays or regulatory hurdles
- • Integration and IT setup fees may apply
- • Annual subscription likely with volume-based pricing
Viability Score
How well maintained and how widely used is InVision Medical Technology? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: August 2026
How we score →Key Features
- Automated LVEF calculation
- AI detection of cardiac amyloidosis
- FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
- Prospective randomized controlled trial published in Nature (2023)
- DICOM-native post-processing
- Vendor-neutral: GE, Philips, Siemens, Canon, handheld POCUS
- PACS and Epic EHR integration
- CPT Category III code 0932T (effective Jan 1, 2025)
- Medicare NTAP for inpatient amyloid (up to $2,275/stay, Oct 1, 2026)
- Breakthrough Device designation for cardiac amyloid
- FDA TAP enrollment
- Zero marginal clinician burden per study
- Multi-indication pipeline (LVEF, amyloid, cirrhosis, reporting, valve disease)
- Precision Cirrhosis for opportunistic liver disease detection
- Precision Reporting with EchoPrime foundation model
About InVision Medical Technology
InVision Medical Technology delivers clinically validated, FDA-cleared AI for echocardiography, the most common cardiac imaging exam worldwide. Its platform, featuring Precision LVEF and Precision Cardiac Amyloid, integrates into existing DICOM workflows without new hardware, automating ejection fraction and detecting undiagnosed cardiac amyloidosis. Backed by over a decade of research published in Nature, Nature Medicine, JAMA Cardiology, and NEJM AI, InVision's algorithms offer proven time savings and improved precision. A CPT Category III code (0932T, effective January 1, 2025) provides direct reimbursement for AI-assisted echo evaluation in heart failure patients. The platform deploys alongside PACS and Epic EHR, with a growing pipeline including Precision Cirrhosis (Breakthrough Device designation) and Precision Reporting powered by the EchoPrime foundation model. Developed in collaboration with Alexion (AstraZeneca Rare Disease), InVision targets health system leaders seeking regulatory-grade, evidence-backed AI with clear ROI.
Behind the Verdict
InVision is not a typical AI vendor. It's a research-driven company with a decade of academic pedigree, two FDA-cleared algorithms, and a rare distinction: a prospective randomized controlled trial published in Nature. That level of evidence is almost unheard of in medical AI. The platform focuses on two core products: Precision LVEF, which automates ejection fraction measurement, and Precision Cardiac Amyloid, which screens for a frequently missed disease. Both run as post-processing on standard DICOM images, so there's no new hardware or acquisition changes. Where InVision shines: regulatory rigor, clinical evidence, and a clear reimbursement path. The CPT Category III code 0932T and the new Medicare NTAP for inpatient amyloid detection (up to $2,275 per stay, effective October 2026) mean your ROI case is grounded in real payment, not just efficiency. The vendor-neutral DICOM support and flexible deployment (on-prem or cloud) make it a strong fit for health systems with existing PACS and Epic. Weaknesses: it's enterprise-only, contact-priced, and not self-service. There's no public pricing, no free trial, and no API documentation. If you're a small clinic or an independent practice, InVision is likely overkill. Also, it's post-processing only—no real-time, scanner-integrated AI. You need to have DICOM infrastructure in place. The roadmap is promising: Precision Cirrhosis has Breakthrough Device designation, and Precision Reporting (powered by EchoPrime, a foundation model) is in development. But those aren't cleared yet, so you're betting on future products. Bottom line: if you run a large cardiology service line and want AI that's evidence-backed, reimbursed, and deployable at scale, InVision is the strongest choice. If you need something quick, cheap, or real-time, look elsewhere.
Researching InVision Medical Technology? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas InVision Medical Technology actually fits — and what changes day-one when you adopt it.
Standardizing echo interpretation across multiple sites to reduce variability and improve efficiency.
Outcome: Deploy Precision LVEF and Precision Cardiac Amyloid in four weeks, automating measurements and flagging amyloid cases without adding clinician workload, improving consistency and supporting population health.
Reducing sonographer and cardiologist time spent on manual LVEF measurements.
Outcome: Implement Precision LVEF to automatically calculate EF from existing DICOM studies, cutting interpretation time per exam and reallocating staff to higher-value tasks.
Building a business case for AI investment with clear reimbursement.
Outcome: Utilize CPT 0932T for outpatient and Medicare NTAP for inpatient to offset costs, with up to $2,275 per eligible stay, turning AI into a revenue-generating service line.
Use Cases
- Automate LVEF measurement from routine echo studies to reduce sonographer and cardiologist effort.
- Screen every routine echo for cardiac amyloidosis without additional clinician workload.
- Standardize echo measurements across a health system for consistent, reproducible results.
- Deploy AI post-processing on existing DICOM studies to surface undiagnosed heart disease.
- Leverage CPT 0932T reimbursement for AI-assisted echo evaluation in heart failure patients.
- Integrate FDA-cleared AI into enterprise PACS/EHR workflow for cardiology service line optimization.
Models Under the Hood
as of 2026-08-18
Limitations
- Pricing is only available via sales inquiry; no self-service or public tiers.
- Integration requires existing PACS and Epic EHR; no details on API availability.
- Limited to post-processing of DICOM images (not real-time).
- Currently two cleared algorithms with a pipeline; no general-purpose AI.
as of 2026-08-17
Verification history
We have re-verified InVision Medical Technology 4 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where InVision Medical Technology's pricing actually pencils out — and where peers do it cheaper.
InVision is contact-priced, fitting large health systems with dedicated IT and budget for enterprise AI. Compared to cheaper, self-service AI tools (e.g., Us2.ai) that offer per-study pricing, InVision's value is in its regulatory grade, peer-reviewed evidence, and reimbursement codes, justifying a higher price for organizations that prioritize evidence and ROI.
Setup time & first value
How long it actually takes to get something useful out of InVision Medical Technology — broken out by persona, not the marketing-page minute.
Typical implementation is about four weeks from kick-off to go-live, according to the vendor. This includes integration with your PACS and Epic EHR, and can be deployed on-premise or in the cloud. For health systems with existing infrastructure, this is a reasonable timeframe for enterprise AI.
Integrations
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with InVision Medical Technology
Common stack mates teams adopt alongside InVision Medical Technology, with the specific reason each pairing earns its keep.
Paige AI
FDA-cleared AI platform for cancer pathology detection and biomarker discovery
Quibim
Regulatory-cleared quantitative imaging biomarkers from MRI for radiology and biopharma
Flatiron Health
Flatiron Health: Oncology real-world evidence platform with AI-powered insights for cancer research and point-of-care decisions.
Featured Head-to-Head Comparisons
Invision Medical Technology vs Isomorphic Labs
InVision Medical Technology and Isomorphic Labs serve entirely different markets. InVision provides clinically deployed, FDA-cleared AI that reduces sonographer workload and detects cardiac amyloidosis in existing echo workflows, with clear reimbursement. Isomorphic Labs is a research-stage drug discovery AI that partners only with large pharma. For a health system seeking immediate ROI through regulatory-approved AI with CPT billing, InVision is the clear choice. Isomorphic Labs is irrelevant for clinical imaging operations.
Invision Medical Technology vs Rapidsos
Invision Medical Technology vs Codametrix
InVision Medical Technology and CodaMetrix serve entirely different clinical and operational domains. InVision is a specialized AI for echocardiography, FDA-cleared with CPT reimbursement, ideal for cardiology departments focused on diagnostic precision and amyloid screening. CodaMetrix is a broad enterprise coding platform with proven ROI for large health systems tackling denial management and staff productivity. The choice depends on whether the buyer's priority is clinical decision support (InVision) or revenue cycle automation (CodaMetrix).
Alternatives to InVision Medical Technology
View allPaige AI
FDA-cleared AI platform for cancer pathology detection and biomarker discovery
Quibim
Regulatory-cleared quantitative imaging biomarkers from MRI for radiology and biopharma
Flatiron Health
Flatiron Health: Oncology real-world evidence platform with AI-powered insights for cancer research and point-of-care decisions.
Frequently Asked Questions
Categories
Used InVision Medical Technology? Help shape our editorial sentiment research.